
    
      This is a prospective, multi-center, single-arm study to evaluate the safety and efficacy of
      BBB disruption using the ExAblate Model 4000 Type 2.0 (220 kHz) system. Patients with
      diagnosis of Probable Alzheimer's Disease may qualify for a clinical trial to have three
      serial ExAblate BBB disruption procedures in specific areas in the brain. This study will be
      conducted at up to 4 sites in the United States and will enroll up to 20 patients.
    
  